Un projet multicentrique suisse pour améliorer la prévention et la récidive après un syndrome coronarien aigu [A Swiss multicentric project to improve the prevention of cardiovascular event recurrence after acute coronary syndromes].

Recurrence of cardiovascular events and mortality remain high after acute coronary syndromes. A Swiss multicentric study, "Inflammation and acute coronary syndromes (ACS)--Novel strategies for prevention and clinical managements", is currently underway with the support of the Swiss National Science Foundation. The study includes a clinical research subproject of which the aim is to assess the impact of the ELIPS program (multi-dimEnsionaL prevention Program after acute coronary Syndrome) on the recurrence of cardiovascular events after an ACS. The basic research sub-projects aim to investigate novel cardiovascular risk biomarkers and genetic determinants of recurrence and to study the role of stem cells after an ACS. Another sub-project will evaluate intracoronary imaging techniques and the efficacy of different types of stents.

[Archives de la Parole]. , Parable of the prodigal son : in Gondi, from Bastar (C.P) [i.e. Central Provinces] - Dravidien - Ling[uistic] survey of India / [Sir George Grierson], éd. ; Linguistic survey of India ; [Kesrī Gond], voix

[Traditions. Asie. Inde. Madhya Pradesh. Chhattisgarh]

Matéria seca, relação C/N e acúmulo de nitrogênio, fósforo e potássio em misturas de plantas de cobertura de solo

O interesse em consorciar plantas de cobertura no inverno tem aumentado nos últimos anos na região Sul do Brasil. Por ser uma prática agrícola recente, é importante avaliar a produção de matéria seca e o acúmulo de nutrientes de espécies consorciadas ou cultivadas isoladamente. Realizou-se um experimento no período de 1998 a 2000, na UFSM (RS), num Argissolo Vermelho distrófico arênico, consorciando-se aveia preta (Avena strigosa Schieb) + ervilhaca comum (Vicia sativa L.) e aveia preta + nabo forrageiro (Raphanus sativus L. var. oleiferus Metzg.) em diferentes quantidades de sementes. Os nove tratamentos foram: (1) 100 % aveia preta (AP); (2) 100 % ervilhaca comum (EC); (3) 100 % nabo forrageiro (NF); (4) 15 % AP + 85 % EC; (5) 30 % AP + 70 % EC; (6) 45 % AP + 55 % EC; (7) 15 % AP + 85 % NF; (8) 30 % AP + 70 % NF, e (9) pousio invernal (vegetação espontânea). Avaliou-se a produção de matéria seca (MS), bem como as concentrações de nitrogênio, fósforo, potássio e carbono do tecido vegetal. O cultivo consorciado de plantas de cobertura proporcionou produção de matéria seca estatisticamente semelhante àquela da aveia e do nabo em culturas isoladas e superior à da ervilhaca. O acúmulo de N na fitomassa dos tratamentos envolvendo consórcio de aveia + ervilhaca não diferiu daquele da ervilhaca isolada e, na média dos três anos, foi superior ao da aveia isolada em 32 kg ha-1 de N. Consorciando aveia + ervilhaca, houve um aumento médio de 67 % na relação C/N da fitomassa, em relação à ervilhaca. As plantas de cobertura proporcionaram maior produção de MS e foram mais eficientes no acúmulo de N, P e K do que a vegetação espontânea do pousio invernal. Os resultados indicaram que o consórcio de aveia + ervilhaca e de aveia + nabo no outono/inverno proporcionou maior produção de biomassa do que o cultivo isolado de cada espécie, pois combinou a elevada capacidade de produção de fitomassa de aveia e nabo com a fixação de N2 atmosférico da ervilhaca.

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

PURPOSE: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node-negative (N(-)) breast cancer patients was reported. The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment. EXPERIMENTAL DESIGN: Gene expression profiling of frozen samples from 198 N(-) systemically untreated patients was done at the Bordet Institute, blinded to clinical data and independent of Veridex. Genomic risk was defined by Veridex, blinded to clinical data. Survival analyses, done by an independent statistician, were done with the genomic risk and adjusted for the clinical risk, defined by Adjuvant! Online. RESULTS: The actual 5- and 10-year time to distant metastasis were 98% (88-100%) and 94% (83-98%), respectively, for the good profile group and 76% (68-82%) and 73% (65-79%), respectively, for the poor profile group. The actual 5- and 10-year overall survival were 98% (88-100%) and 87% (73-94%), respectively, for the good profile group and 84% (77-89%) and 72% (63-78%), respectively, for the poor profile group. We observed a strong time dependence of this signature, leading to an adjusted hazard ratio of 13.58 (1.85-99.63) and 8.20 (1.10-60.90) at 5 years and 5.11 (1.57-16.67) and 2.55 (1.07-6.10) at 10 years for time to distant metastasis and overall survival, respectively. CONCLUSION: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.

Decrease in the prevalence of hepatitis B and a low prevalence of hepatitis C virus infections in the general population of the Seychelles.

A serological survey of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections was carried out on a random sex- and age-stratified sample of 1006 individuals aged 25-64 years in the Seychelles islands. Anti-HBc and anti-HCV antibodies were detected using commercially available enzyme-linked immunosorbent assays (ELISA), followed by a Western blot assay in the case of a positive result for anti-HCV. The age-adjusted seroprevalence of anti-HBc antibodies was 8.0% (95% CI: 6.5-9.9%) and the percentage prevalence among males/females increased from 7.0/3.1 to 19.1/13.4 in the age groups 25-34 to 55-64 years, respectively. Two men and three women were positive for anti-HCV antibodies, with an age-adjusted seroprevalence of 0.34% (95% CI: 0.1-0.8%). Two out of these five subjects who were positive for anti-HCV also had anti-HBc antibodies. The seroprevalence of anti-HBc was significantly higher in unskilled workers, persons with low education, and heavy drinkers. The age-specific seroprevalence of anti-HBc in this population-based survey, which was conducted in 1994, was approximately three times lower than in a previous patient-based survey carried out in 1979. Although there are methodological differences between the two surveys, it is likely that the substantial decrease in anti-HBc prevalence during the last 15 years may be due to significant socioeconomic development and the systematic screening of blood donors since 1981. Because hepatitis C virus infections are serious and the cost of treatment is high, the fact that the prevalence of anti-HCV antibodies is at present low should not be an argument for not screening blood donors for anti-HCV and eliminating those who are positive.

Pas un iota ne passera de la Loi... (Mt 5,18). La Loi dans l'évangile de Matthieu

(Résumé de l'ouvrage) La loi occupe une place essentielle dans l'ensemble de la bibliothèque biblique. Quel rôle y joue-t-elle ? Quand et à quelles conditions fonctionne-t-elle comme bonne ou mauvaise nouvelle pour les acteurs et pour les lecteurs ?

Treatment of chronic hepatitis C.

Treatment for chronic hepatitis C has changed over the past years achieving higher response rates. The combination treatment with pegylated interferon-a and ribavirin is tailored based on the on-treatment virological responses. With this response-guided therapy, the overall sustained virological response rate is about 55%. Many new antivirals are currently under investigation and some will be commercially available in the near future. These include antiviral molecules acting directly against the hepatitis C virus (HCV) replication machinery, such as the inhibitors of the viral protease, and agents binding to host cofactors of the viral replication, thereby inhibiting HCV in an indirect way (such as cyclophilin inhibitors and nitazoxanide). The advent of these drugs will further ameliorate response rates and facilitate the permanent cure of chronic hepatitis C.